Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.
By B. Burtness, M. Goldwasser, W. Flood, B. Mattar, A. Forastiere. Journal of Clinical Oncology, 2005
812 citations recorded by the source corpus.
Subfields: Molecular Biology, Otorhinolaryngology, Periodontics
View Paper: https://www.semanticscholar.org/paper/00effb3f58a8c4fd8cb3e8088efdc2ccab6221f3
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
Citations in the corpus
- ERBB receptors: From oncogene discovery to basic science to mechanism-based cancer therapeutics (2014, background): “…of EGFR expression by IHC for patient selection in head and neck cancers (and CRCs), there currently are no validated predictive biomarkers of response to EGFR inhibitors in head and neck cancers (Burtness et al., 2005; Cunningham et al., 2004; Licitra et al., 2011, 2013; Vermorken et al., 2008).”
- Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. (2014, background): “Furthermore, in patients with metastatic disease, adding cetuximab to cisplatin increased the response rate.(11) Another”